Yasir Y Elamin, MD

Peer-Reviewed Articles

1. Hong L, Di Federico A, Liu B, Cooper AJ, Alessi JV, Clark P, Rinsurongkawong W, Young C, Li H, Qin K, Aminu M, Santo V, Elamin Y, Sepesi B, Lewis J, Gibbons DL, Vaporciyan AA, Lee JJ, Le X, Wu J, Roy-Chowdhuri S, Routbort MJ, Futreal PA, Heymach JV, Awad MM, Schoenfeld AJ, Zhang J, Ricciuti B, Deng L, Vokes NI. Distinct Clinicogenomic Features and Immunotherapy Associations in Pulmonary Sarcomatoid Carcinoma: A Multicenter Retrospective Study. J Thorac Oncol 20(12):1763-1777, 2025. e-Pub 2025. PMID: 40716572.
2. Li H, Hong L, Rocha P, Bach R, Solis Soto LM, Rinsurongkawong W, Zhang B, Araujo HA, Elamin YY, Altan M, Arrechedera CA, Zhou J, Khan KB, Lu W, Young E, Gay CM, Cascone T, Byers LA, Skoulidis F, Blumenschein G, Fossella FV, Tsao A, Negrao MV, Vokes N, Wu J, Tran HT, Wistuba II, Lee JJ, Gibbons DL, Vaporciyan AA, Heymach JV, Le X, Zhang J. MET Overexpression Is Associated with Superior Immunotherapy Benefit in Advanced Non-Small Cell Lung Cancer. Cancers (Basel) 17(23), 2025. e-Pub 2025. PMID: 41375002.
3. Le X, Robichaux JP, Nilsson M, Vijayan RSK, Ravichandran A, Wu J, Elamin YY, Hong L, Pei J, He J, Patel S, Udagawa H, Mani S, Jang CW, Clarke JM, Tchekmedyian N, Goldman JW, Socinski M, Bhat G, Leu S, Bunn V, Su Z, Vincent S, Lawson JW, Cross JB, Heymach JV. Poziotinib for EGFR exon 20-insertion NSCLC: Clinical efficacy of the phase 2 ZENITH trial and differential impact of EGFR exon 20 insertion location on sensitivity. Nat Commun 16(1):8358, 2025. e-Pub 2025. PMID: 40993146.
4. Patil T, Lin JJ, Cheema PK, Carrizosa DR, Burkard ME, Elamin YY, Desai J, Patel JD, Nagasaka M, Reckamp KL, Waqar SN, Bauman JR, Schram AM, Gadgeel SM, Ma PC, Konduri K, Nguyen D, Misleh J, Bleeker J, Weiss M, Thavaneswaran S, Haura EB, Deegan M, Kaufman J, Srivastava J, Jansen VM, Liu SV. CRESTONE: A Phase II Study of the Efficacy and Safety of the HER3 Monoclonal Antibody, Seribantumab, in Solid Tumors With Neuregulin-1 (NRG1) Fusions. JCO Precis Oncol 9:e2500221, 2025. e-Pub 2025. PMID: 41428976.
5. Saad MB, Al-Tashi Q, Hong L, Verma V, Li W, Boiarsky D, Li S, Petranovic M, Wu CC, Carter BW, Shroff GS, Cascone T, Le X, Elamin YY, Altan M, Heeke S, Sheshadri A, Chang JY, Lee PP, Liao Z, Gibbons DL, Vaporciyan AA, Lee JJ, Wistuba II, Haymaker C, Mirjalili S, Jaffray D, Gainor JF, Lou Y, Di Federico A, Pecci F, Awad M, Ricciuti B, Heymach JV, Vokes NI, Zhang J, Wu J. Machine-learning driven strategies for adapting immunotherapy in metastatic NSCLC. Nat Commun 16(1):6828, 2025. e-Pub 2025. PMID: 40707438.
6. Heeke, S, Gandhi, S, Tran, HT, Lam, VK, Byers, LA, Gibbons, DL, Gay, CM, Altan, M, Antonoff, MB, Le, X, Tu, J, Saad, M, Pek, M, Poh, J, Ngeow, KC, Tsao, A, Cascone, T, Vailati Negrao, M, Wu, J, Blumenschein, GR, Heymach, JV, Elamin, YY. Longitudinal Tracking of ALK-Rearranged NSCLC From Plasma Using Circulating Tumor RNA and Circulating Tumor DNA. JTO Clinical and Research Reports 6(4), 2025. e-Pub 2025. PMID: 40160974.
7. Xia, Y, Wang, K, Zhao, J, Arter, Z, Zhang, Y, Zhou, J, Lu, Y, Zeng, L, Du, R, Owens, J, Elamin, YY, Gay, CM, Skoulidis, F, Tsao, A, Lu, C, Cascone, T, Gibbons, DL, Zhang, J, Chen, O, Mok, K, Nagasaka, M, Li, W, Heymach, JV, Ignatius Ou, SH, Li, M, Le, X. Receptor Tyrosine Kinase Fusion-Mediated Resistance to EGFR TKI in EGFR-Mutant NSCLC. Journal of Thoracic Oncology 20(4):465-474, 2025. e-Pub 2025. PMID: 39622411.
8. Antonoff, MB, Mitchel, KG, Kim, S, Salfity, HV, Kotova, S, Ripley, RT, Neri, AL, Sood, P, Gandhi, SG, Elamin, YY, Donington, J, Jones, DR, David, E, Swisher, SG, Opitz, I, Hayanga, JW, Rocco, G. The Society of Thoracic Surgeons (STS) Clinical Practice Guideline on Surgical Management of Oligometastatic Non-small Cell Lung Cancer. Annals of Thoracic Surgery 119(3):495-508, 2025. e-Pub 2025. PMID: 39797869.
9. Zhou N, Leung CH, William WN Jr, Weissferdt A, Pataer A, Godoy MCB, Carter BW, Fossella FV, Tsao AS, Blumenschein GR, Le X, Zhang J, Skoulidis F, Kurie JM, Altan M, Lu C, Glisson BS, Byers LA, Elamin YY, Mehran RJ, Rice DC, Walsh GL, Hofstetter WL, Roth JA, Tran HT, Wu J, Solis Soto LM, Kadara H, Swisher SG, Vaporciyan AA, Gibbons DL, Lin HY, Lee JJ, Heymach JV, Negrao MV, Sepesi B, Cascone T. Impact of select actionable genomic alterations on efficacy of neoadjuvant immunotherapy in resectable non-small cell lung cancer. J Immunother Cancer 12(10), 2024. e-Pub 2024. PMID: 39448200.
10. Skoulidis F, Araujo HA, Do MT, Qian Y, Sun X, Cobo AG, Le JT, Montesion M, Palmer R, Jahchan N, Juan JM, Min C, Yu Y, Pan X, Arbour KC, Vokes N, Schmidt ST, Molkentine D, Owen DH, Memmott R, Patil PD, Marmarelis ME, Awad MM, Murray JC, Hellyer JA, Gainor JF, Dimou A, Bestvina CM, Shu CA, Riess JW, Blakely CM, Pecot CV, Mezquita L, Tabbo F, Scheffler M, Digumarthy S, Mooradian MJ, Sacher AG, Lau SCM, Saltos AN, Rotow J, Johnson RP, Liu C, Stewart T, Goldberg SB, Killam J, Walther Z, Schalper K, Davies KD, Woodcock MG, Anagnostou V, Marrone KA, Forde PM, Ricciuti B, Venkatraman D, Van Allen EM, Cummings AL, Goldman JW, Shaish H, Kier M, Katz S, Aggarwal C, Ni Y, Azok JT, Segal J, Ritterhouse L, Neal JW, Lacroix L, Elamin YY, Negrao MV, Le X, Lam VK, Lewis WE, Kemp HN, Carter B, Roth JA, Swisher S, Lee R, Zhou T, Poteete A, Kong Y, Takehara T, Paula AG, Parra Cuentas ER, Behrens C, Wistuba II, Zhang J, Blumenschein GR, Gay C, Byers LA, Gibbons DL, Tsao A, Lee JJ, Bivona TG, Camidge DR, Gray JE, Lieghl N, Levy B, Brahmer JR, Garassino MC, Gandara DR, Garon EB, Rizvi NA, Scagliotti GV, Wolf J, Planchard D, Besse B, Herbst RS, Wakelee HA, Pennell NA, Shaw AT, Janne PA, Carbone DP, Hellmann MD, Rudin CM, Albacker L, Mann H, Zhu Z, Lai Z, Stewart R, Peters S, Johnson ML, Wong KK, Huang A, Winslow MM, Rosen MJ, Winters IP, Papadimitrakopoulou VA, Cascone T, Jewsbury P, Heymach JV. CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors. Nature 635(8038):462-471, 2024. e-Pub 2024. PMID: 39385035.
11. Le X, Patel JD, Shum E, Baik C, Sanborn RE, Shu CA, Kim C, Fidler MJ, Hall R, Elamin YY, Tu J, Blumenschein G, Zhang J, Gibbons D, Gay C, Mohindra NA, Chae Y, Boumber Y, Sabari J, Santana-Davila R, Rogosin S, Herzberg B, Creelan B, Pellini B, Tanvetyanon T, Heeke S, Hernandez M, Gray JE, Saltos A, Heymach JV. A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor-Naive EGFR-Mutant Metastatic Non-Small Cell Lung Cancer (RAMOSE trial). J Clin Oncol 43(4):JCO2400533, 2024. e-Pub 2024. PMID: 39378386.
12. Pan, K, Owens, J, Elamin, YY, Lu, C, Routbort, MJ, Zhang, J, Fossella, FV, Vailati Negrao, M, Altan, M, Pozadzides, JV, Skoulidis, F, Tsao, A, Cascone, T, Heymach, JV, Ostrin, EJ, Le, X. Mutational Characteristics and Clinical Outcomes for Lung Adenocarcinoma With EGFR Germline Mutations. Journal of Thoracic Oncology 19(10):1438-1448, 2024. e-Pub 2024. PMID: 38866326.
13. Sujit SJ, Aminu M, Karpinets TV, Chen P, Saad MB, Salehjahromi M, Boom JD, Qayati M, George JM, Allen H, Antonoff MB, Hong L, Hu X, Heeke S, Tran HT, Le X, Elamin YY, Altan M, Vokes NI, Sheshadri A, Lin J, Zhang J, Lu Y, Behrens C, Godoy MCB, Wu CC, Chang JY, Chung C, Jaffray DA, Wistuba II, Lee JJ, Vaporciyan AA, Gibbons DL, Heymach J, Zhang J, Cascone T, Wu J. Enhancing NSCLC recurrence prediction with PET/CT habitat imaging, ctDNA, and integrative radiogenomics-blood insights. Nat Commun 15(1):3152, 2024. e-Pub 2024. PMID: 38605064.
14. Zhang, B, Lewis, WE, Stewart, C, Morris, BB, Solis Soto, LM, Serrano, A, Xi, Y, Wang, Q, Lopez, ER, Concannon, K, Heeke, S, Tang, X, Raso, G, Cardnell, R, Vokes, N, Blumenschein, GR, Elamin, YY, Fosella, F, Tsao, A, Skoulidis, F, Hume, CB, Sasak, K, Lewis, J, Rinsurongkawong, W, Rinsurongkawong, V, Lee, JJ, Tran, HT, Zhang, J, Gibbons, DL, Vaporciyan, AA, Wang, J, Park, K, Heymach, JV, Byers, LA, Gay, CM, Le, X. Brief Report. JTO Clinical and Research Reports 5(2), 2024. e-Pub 2024. PMID: 38357092.
15. Katlowitz KA, Beckham TH, Kudchadker RJ, Wefel J, Elamin YY, Weinberg JS. A Novel Multimodal Approach to Refractory Brain Metastases: A Case Report. Adv Radiat Oncol 9(2):101349, 2024. e-Pub 2024. PMID: 38405307.
16. Udagawa H, Nilsson MB, Robichaux JP, He J, Poteete A, Jiang H, Heeke S, Elamin YY Shibata Y, Matsumoto S, Yoh K, Okazaki S, Masuko T, Odintsov I, Somwar R, Ladanyi M, Goto K, Heymach JV. HER4 and EGFR activate cell signaling in NRG1 fusion-driven cancers: implications for HER2/HER3-specific vs. pan-HER targeting strategies. J Thorac Oncol 19(1):106-118, 2024. e-Pub 2024. PMID: 37678511.
17. Zhou C, Solomon B, Loong HH, Park K, Pérol M, Arriola E, Novello S, Han B, Zhou J, Ardizzoni A, Mak MP, Santini FC, Elamin YY, Drilon A, Wolf J, Payakachat N, Uh MK, Rajakumar D, Han H, Puri T, Soldatenkova V, Lin AB, Lin BK, Goto K, Investigators LT. First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC. N Engl J Med 389(20):1839-1850, 2023. e-Pub 2023. PMID: 37870973.
18. Chang JY, Lin SH, Dong W, Liao Z, Gandhi SJ, Gay CM, Zhang J, Chun SG, Elamin YY, Fossella FV, Blumenschein G, Cascone T, Le X, Pozadzides JV, Tsao A, Verma V, Welsh JW, Chen AB, Altan M, Mehran RJ, Vaporciyan AA, Swisher SG, Balter PA, Fujimoto J, Wistuba II, Feng L, Lee JJ, Heymach JV. Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial. Lancet 402(10405):871-881, 2023. e-Pub 2023. PMID: 37478883.
19. Wang K, Du R, Roy-Chowdhuri S, Li ZT, Hong L, Vokes N, Elamin YY, Hume CB, Skoulidis F, Gay CM, Blumenschein G, Fossella FV, Tsao A, Zhang J, Karachaliou N, O'Brate A, Gann CN, Lewis J, Rinsurongkawong W, Lee JJ, Gibbons DL, Vaporciyan AA, Heymach JV, Altan M, Le X. Brief Report: Clinical Response, Toxicity, and Resistance Mechanisms to Osimertinib Plus MET Inhibitors in Patients With EGFR-Mutant MET-Amplified NSCLC. JTO Clin Res Rep 4(8):100533, 2023. e-Pub 2023. PMID: 37649681.
20. Saad MB, Hong L, Aminu M, Vokes NI, Chen P, Salehjahromi M, Qin K, Sujit SJ, Lu X, Young E, Al-Tashi Q, Qureshi R, Wu CC, Carter BW, Lin SH, Lee PP, Gandhi S, Chang JY, Li R, Gensheimer MF, Wakelee HA, Neal JW, Lee HS, Cheng C, Velcheti V, Lou Y, Petranovic M, Rinsurongkawong W, Le X, Rinsurongkawong V, Spelman A, Elamin YY, Negrao MV, Skoulidis F, Gay CM, Cascone T, Antonoff MB, Sepesi B, Lewis J, Wistuba II, Hazle JD, Chung C, Jaffray D, Gibbons DL, Vaporciyan A, Lee JJ, Heymach JV, Zhang J, Wu J. Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective study. Lancet Digit Health 5(7):e404-e420, 2023. e-Pub 2023. PMID: 37268451.
21. Altan M, Wang Y, Song J, Welsh J, Tang C, Guha-Thakurta N, Blumenschein GR, Carter BW, Wefel JS, Ghia AJ, Yeboa DN, McAleer MF, Chung C, Woodhouse KD, McGovern SL, Wang C, Kim BYS, Weinberg JS, Briere TM, Elamin YY, Le X, Cascone T, Negrao MV, Skoulidis F, Ferrarotto R, Heymach JV, Li J. Nivolumab and ipilimumab with concurrent stereotactic radiosurgery for intracranial metastases from non-small cell lung cancer: analysis of the safety cohort for non-randomized, open-label, phase I/II trial. J Immunother Cancer 11(7), 2023. e-Pub 2023. PMID: 37402581.
22. Chu Y, Dai E, Li Y, Han G, Pei G, Ingram DR, Thakkar K, Qin JJ, Dang M, Le X, Hu C, Deng Q, Sinjab A, Gupta P, Wang R, Hao D, Peng F, Yan X, Liu Y, Song S, Zhang S, Heymach JV, Reuben A, Elamin YY, Pizzi MP, Lu Y, Lazcano R, Hu J, Li M, Curran M, Futreal A, Maitra A, Jazaeri AA, Ajani JA, Swanton C, Cheng XD, Abbas HA, Gillison M, Bhat K, Lazar AJ, Green M, Litchfield K, Kadara H, Yee C, Wang L. Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance. Nat Med 29(6):1550-1562, 2023. e-Pub 2023. PMID: 37248301.
23. Richards CE, Elamin YY, Carr A, Gately K, Rafee S, Cremona M, Hanrahan E, Smyth R, Ryan D, Morgan RK, Kennedy S, Hudson L, Fay J, O'Byrne K, Hennessy BT, Toomey S. Protein Tyrosine Phosphatase Non-Receptor 11 (PTPN11/Shp2) as a Driver Oncogene and a Novel Therapeutic Target in Non-Small Cell Lung Cancer (NSCLC). Int J Mol Sci 24(13), 2023. e-Pub 2023. PMID: 37445722.
24. Ferrarotto, R, Guimares de Sousa, L, Feng, L, Mott, FE, Blumenschein, GR, Altan, M, Bell, D, Bonini, F, Li, K, Marques-Piubelli, ML, Dal Lago, EA, Johnson, JJ, Mitani, Y, Godoy, M, Lee, A, Kupferman, ME, Hanna, EY, Glisson, BS, Elamin, YY, El-Naggar, AK. Phase II Clinical Trial of Axitinib and Avelumab in Patients With Recurrent/Metastatic Adenoid Cystic Carcinoma. Journal of Clinical Oncology 41(15):2843-2851, 2023. e-Pub 2023. PMID: 36898078.
25. Le X, Elamin YY, Zhang J. New Actions on Actionable Mutations in Lung Cancers. Cancers (Basel) 15(11), 2023. e-Pub 2023. PMID: 37296880.
26. Patel SA, Nilsson MB, Yang Y, Le X, Tran HT, Elamin YY, Yu X, Zhang F, Poteete A, Ren X, Shen L, Wang J, Moghaddam SJ, Cascone T, Curran M, Gibbons DL, Heymach JV. IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC. Clin Cancer Res 29(7):1292-1304, 2023. e-Pub 2023. PMID: 36595561.
27. Cascone T, Leung CH, Weissferdt A, Pataer A, Carter BW, Godoy MCB, Feldman H, William WN, Xi Y, Basu S, Sun JJ, Yadav SS, Rojas Alvarez FR, Lee Y, Mishra AK, Chen L, Pradhan M, Guo H, Sinjab A, Zhou N, Negrao MV, Le X, Gay CM, Tsao AS, Byers LA, Altan M, Glisson BS, Fossella FV, Elamin YY, Blumenschein G, Zhang J, Skoulidis F, Wu J, Mehran RJ, Rice DC, Walsh GL, Hofstetter WL, Rajaram R, Antonoff MB, Fujimoto J, Solis LM, Parra ER, Haymaker C, Wistuba II, Swisher SG, Vaporciyan AA, Lin HY, Wang J, Gibbons DL, Jack Lee J, Ajami NJ, Wargo JA, Allison JP, Sharma P, Kadara H, Heymach JV, Sepesi B. Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial. Nat Med 29(3):593-604, 2023. e-Pub 2023. PMID: 36928818.
28. Hong L, Aminu M, Li S, Lu X, Petranovic M, Saad MB, Chen P, Qin K, Varghese S, Rinsurongkawong W, Rinsurongkawong V, Spelman A, Elamin YY, Negrao MV, Skoulidis F, Gay CM, Cascone T, Gandhi SJ, Lin SH, Lee PP, Carter BW, Wu CC, Antonoff MB, Sepesi B, Lewis J, Gibbons DL, Vaporciyan AA, Le X, Jack Lee J, Roy-Chowdhuri S, Routbort MJ, Gainor JF, Heymach JV, Lou Y, Wu J, Zhang J, Vokes NI. Efficacy and clinicogenomic correlates of response to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancer. Nat Commun 14(1):695, 2023. e-Pub 2023. PMID: 36755027.
29. Nilsson MB, Yang Y, Heeke S, Patel SA, Poteete A, Udagawa H, Elamin YY, Moran CA, Kashima Y, Arumugam T, Yu X, Ren X, Diao L, Shen L, Wang Q, Zhang M, Robichaux JP, Shi C, Pfeil AN, Tran H, Gibbons DL, Bock J, Wang J, Minna JD, Kobayashi SS, Le X, Heymach JV. CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance. Cancer Cell 41(2):340-355.e6, 2023. e-Pub 2023. PMID: 36787696.
30. De B, Farooqi AS, Mitchell KG, Ludmir EB, Lewis J, Rinsurongkawong W, Rinsurongkawong V, Lee JJ, Swisher SG, Gibbons DL, Zhang J, Le X, Elamin YY, Gomez DR, Ning MS, Lin SH, Liao Z, Chang JY, Vaporciyan AA, Heymach JV, Antonoff MB, Gandhi SJ. Benchmarking Outcomes for Molecularly Characterized Synchronous Oligometastatic Non-Small-Cell Lung Cancer Reveals EGFR Mutations to Be Associated With Longer Overall Survival. JCO Precis Oncol 7:e2200540, 2023. e-Pub 2023. PMID: 36716413.
31. Drilon, A, Besse, B, Camidge, DR, Ignatius Ou, SH, Gadgeel, S, Johnson, M, Calles-Blanco, A, de Miguel, MJ, Spira, AI, Felip, E, Lopes, G, van der Wekken, AJ, Elamin, YY, Green, JA, Sun, Y, Soglia, J, Zhu, VW, Lin, JJ. Safety and preliminary clinical activity of NVL-520, a highly selective ROS1 inhibitor, in patients with advanced ROS1 fusion-positive solid tumors. European Journal of Cancer 174:S6-S7, 2022. e-Pub 2022.
32. Khan TM, Verbus EA, Gandhi S, Heymach JV, Hernandez JM, Elamin YY. Osimertinib, Surgery, and Radiation Therapy in Treating Patients with Stage IIIB or IV Non-Small Cell Lung Cancer with EGFR Mutations (NORTHSTAR). Ann Surg Oncol 29(8):4688-4689, 2022. e-Pub 2022. PMID: 35527328.
33. Elamin YY, Robichaux JP, Carter BW, Altan M, Tran H, Gibbons DL, Heeke S, Fossella FV, Lam VK, Le X, Negrao MV, Nilsson MB, Patel A, Vijayan RSK, Cross JB, Zhang J, Byers LA, Lu C, Cascone T, Feng L, Luthra R, San Lucas FA, Mantha G, Routbort M, Blumenschein G, Tsao AS, Heymach JV. Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity. Cancer Cell 40(7):754-767.e6, 2022. e-Pub 2022. PMID: 35820397.
34. Hong L, Lewis WE, Nilsson M, Patel S, Varghese S, Rivera MJ, Du RR, Chen P, Kemp HN, Rinsurongkawong W, Heeke S, Spelman AR, Elamin YY, Negrao MV, Sepesi B, Gibbons DL, Lee JJ, Wu J, Vokes NI, Heymach JV, Zhang J, Le X. Limited Benefit from the Addition of Immunotherapy to Chemotherapy in TKI-Refractory EGFR-Mutant Lung Adenocarcinoma. Cancers (Basel) 14(14), 2022. e-Pub 2022. PMID: 35884533.
35. Elamin YY, Robichaux JP, Carter BW, Altan M, Gibbons DL, Fossella FV, Lam VK, Patel AB, Negrao MV, Le X, Mott FE, Zhang J, Feng L, Blumenschein G, Tsao AS, Heymach JV. Poziotinib for Patients With HER2 Exon 20 Mutant Non-Small-Cell Lung Cancer: Results From a Phase II Trial. J Clin Oncol 40(7):JCO2101113, 2022. e-Pub 2022. PMID: 34550757.
36. Mezynski, MJ, Farrelly, A, Cremona, M, Carr, A, Morgan, C, Workman, J, Armstrong, P, McAuley, J, Madden, S, Fay, J, Sheehan, KM, Kay, EW, Holohan, C, Elamin, YY, Rafee, S, Morris, P, Breathnach, O, Grogan, L, Hennessy, BT, Toomey, S. Targeting the PI3K and MAPK pathways to improve response to HER2-targeted therapies in HER2-positive gastric cancer. Journal of translational medicine 19(1), 2021. e-Pub 2021. PMID: 33933113.
37. Farooqi, AS, Ludmir, EB, Mitchell, KG, Antonoff, MB, Tang, C, Lee, PP, Chang, JY, Elamin, YY, Gomez, D, Gandhi, S. Increased biologically effective dose (BED) to the primary tumor is associated with improved survival in patients with oligometastatic NSCLC. Radiotherapy and Oncology 163:114-118, 2021. e-Pub 2021. PMID: 34419505.
38. Robichaux JP, Le X, Vijayan RSK, Hicks JK, Heeke S, Elamin YY, Lin HY, Udagawa H, Skoulidis F, Tran H, Varghese S, He J, Zhang F, Nilsson MB, Hu L, Poteete A, Rinsurongkawong W, Zhang X, Ren C, Liu X, Hong L, Zhang J, Diao L, Madison R, Schrock AB, Saam J, Raymond V, Fang B, Wang J, Ha MJ, Cross JB, Gray JE, Heymach JV. Structure-based classification predicts drug response in EGFR-mutant NSCLC. Nature 597(7878):732-737, 2021. e-Pub 2021. PMID: 34526717.
39. Tran HT, Lam VK, Elamin YY, Hong L, Colen R, Elshafeey NA, Hassan ISA, Altan M, Blumenschein GR, Rinsurongkawong W, Rivera MJ, Vasquez ME, Carter BW, Byers LE, Tsao AS, Gibbons DL, Fossella F, Glisson BS, Zhang J, Heymach JV. Clinical Outcomes in Non-Small-Cell Lung Cancer Patients Treated With EGFR-Tyrosine Kinase Inhibitors and Other Targeted Therapies Based on Tumor Versus Plasma Genomic Profiling. JCO Precis Oncol 5:1241-1249, 2021. e-Pub 2021. PMID: 34377884.
40. Negrao MV, Skoulidis F, Montesion M, Schulze K, Bara I, Shen V, Xu H, Hu S, Sui D, Elamin YY, Le X, Goldberg ME, Murugesan K, Wu CJ, Zhang J, Barreto DS, Robichaux JP, Reuben A, Cascone T, Gay CM, Mitchell KG, Hong L, Rinsurongkawong W, Roth JA, Swisher SG, Lee J, Tsao A, Papadimitrakopoulou V, Gibbons DL, Glisson BS, Singal G, Miller VA, Alexander B, Frampton G, Albacker LA, Shames D, Zhang J, Heymach JV. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer. J Immunother Cancer 9(8), 2021. e-Pub 2021. PMID: 34376553.
41. Le, X, Vailati Negrao, M, Reuben, A, Federico, L, Diao, L, McGrail, DJ, Nilsson, M, Robichaux, JP, Munoz, IG, Patel, S, Elamin, YY, Fan, YH, Lee, WC, Parra Cuentas, ER, Solis Soto, LM, Chen, R, Li, J, Karpinets, T, Khairullah, R, Kadara, HN, Behrens, MC, Sepesi, B, Wang, R, Zhu, M, Wang, L, Vaporciyan, AA, Roth, JA, Swisher, SG, Haymaker, CL, Zhang, J, Wang, J, Wong, KK, Byers, LA, Bernatchez, C, Zhang, J, Wistuba, II, Gibbons, DL, Akbay, EA, Heymach, JV. Characterization of the Immune Landscape of EGFR-Mutant NSCLC Identifies CD73/Adenosine Pathway as a Potential Therapeutic Target. Journal of Thoracic Oncology 16(4):583-600, 2021. e-Pub 2021. PMID: 33388477.
42. Nilsson, M, Robichaux, JP, Herynk, MH, Cascone, T, Le, X, Elamin, YY, Patel, S, Zhang, F, Xu, L, Hu, L, Diao, L, Shen, L, He, J, Yu, X, Nikolinakos, P, Saintigny, P, Fang, B, Girard, L, Wang, J, Minna, J, Wistuba, II, Heymach, JV. Altered Regulation of HIF-1α in Naive- and Drug-Resistant EGFR-Mutant NSCLC. Journal of Thoracic Oncology 16(3):439-451, 2021. e-Pub 2021. PMID: 33309987.
43. Schwalk AJ, Ost DE, Saltijeral SN, De La Garza H, Casal RF, Jimenez CA, Eapen GA, Lewis J, Rinsurongkawong W, Rinsurongkawong V, Lee J, Elamin YY, Zhang J, Roth JA, Swisher S, Heymach J, Grosu HB. Risk Factors for and Time to Recurrence of Symptomatic Malignant Pleural Effusion in Patients with Metastatic Non-Small Cell Lung Cancer with EGFR or ALK Mutations. Chest 159(3):1256-1264, 2021. e-Pub 2020. PMID: 33217413.
44. Solomon BJ, Zhou CC, Drilon A, Park K, Wolf J, Elamin YY, Davis HM, Soldatenkova V, Sashegyi A, Lin AB, Lin BK, F Loong HH, Novello S, Arriola E, Pérol M, Goto K, Santini FC. Phase III study of selpercatinib vs chemotherapy +/- pembrolizumab in untreated RET positive non-small-cell lung cancer. Future Oncol 17(7):763-773, 2021. e-Pub 2021. PMID: 33150799.
45. Cascone T, William WN, Weissferdt A, Leung CH, Lin HY, Pataer A, Godoy MCB, Carter BW, Federico L, Reuben A, Khan MAW, Dejima H, Francisco-Cruz A, Parra ER, Solis LM, Fujimoto J, Tran HT, Kalhor N, Fossella FV, Mott FE, Tsao AS, Blumenschein G, Le X, Zhang J, Skoulidis F, Kurie JM, Altan M, Lu C, Glisson BS, Byers LA, Elamin YY, Mehran RJ, Rice DC, Walsh GL, Hofstetter WL, Roth JA, Antonoff MB, Kadara H, Haymaker C, Bernatchez C, Ajami NJ, Jenq RR, Sharma P, Allison JP, Futreal A, Wargo JA, Wistuba II, Swisher SG, Lee JJ, Gibbons DL, Vaporciyan AA, Heymach JV, Sepesi B. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nat Med 27(3):504-514, 2021. e-Pub 2021. PMID: 33603241.
46. Elamin Y, AlAnazi A, Al Saeed ZA, Alabdrabalnabi FM. ADIPSIC DIABETES INSIPIDUS AFTER SECOND RESECTION OF A HYPOTHAMIC ASTROCYTOMA. AACE Clin Case Rep 6(6):e295-e299, 2020. e-Pub 2020. PMID: 33244488.
47. Hegde A, Andreev-Drakhlin AY, Roszik J, Huang L, Liu S, Hess K, Cabanillas M, Hu MI, Busaidy NL, Sherman SI, Dadu R, Grubbs EG, Ali SM, Lee J, Elamin YY, Simon GR, Blumenschein GR, Papadimitrakopoulou VA, Hong D, Meric-Bernstam F, Heymach J, Subbiah V. Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies. ESMO Open 5(5):e000799, 2020. e-Pub 2020. PMID: 33097651.
48. Hong L, Negrao MV, Dibaj SS, Chen R, Reuben A, Bohac JM, Liu X, Skoulidis F, Gay CM, Cascone T, Mitchell KG, Tran HT, Le X, Byers LA, Sepesi B, Altan M, Elamin YY, Fossella FV, Kurie JM, Lu C, Mott FE, Tsao AS, Rinsurongkawong W, Lewis J, Gibbons DL, Glisson BS, Blumenschein GR, Roarty EB, Futreal PA, Wistuba II, Roth JA, Swisher SG, Papadimitrakopoulou VA, Heymach JV, Lee JJ, Simon GR, Zhang J. Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC. J Thorac Oncol 15(9):1449-1459, 2020. e-Pub 2020. PMID: 32389639.
49. Ferrarotto R, Bell D, Rubin ML, Hutcheson KA, Johnson JM, Goepfert RP, Phan J, Elamin YY, Torman DK, Warneke CL, Hessel AC, Garden AS, Myers JN, Johnson FM, Lee JJ, Sikora AG, Gillison ML, Glisson BS, Gross ND. Impact of Neoadjuvant Durvalumab with or without Tremelimumab on CD8+ Tumor Lymphocyte Density, Safety, and Efficacy in Patients with Oropharynx Cancer: CIAO Trial Results. Clin Cancer Res 26(13):3211-3219, 2020. e-Pub 2020. PMID: 32269052.
50. Madison RW, Gupta SV, Elamin YY, Lin DI, Pal SK, Necchi A, Miller VA, Ross JS, Chung JH, Alexander BM, Schrock AB, Heymach JV, Reddy P, Ali SM. Urothelial Cancer Harbors EGFR and HER2 Amplifications and Exon 20 Insertions. BJU Int 125(5):739-746, 2020. e-Pub 2020. PMID: 31985116.
51. Robichaux JP, Elamin YY Vijayan RSK, Nilsson MB, Hu L, He J, Zhang F, Pisegna M, Poteete A, Sun H, Li S, Chen T, Han H, Negrao MV, Ahnert JR, Diao L, Wang J, Le X, Meric-Bernstam F, Routbort M, Roeck B, Yang Z, Raymond VM, Lanman RB, Frampton GM, Miller VA, Schrock AB, Albacker LA, Wong KK, Cross JB, Heymach JV. Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity. Cancer Cell 37(3):420, 2020. e-Pub 2020. PMID: 32183953.
52. Jin Y, Bao H, Le X, Fan X, Tang M, Shi X, Zhao J, Yan J, Xu Y, Quek K, Elamin YY, Zhang J, Futreal PA, Wistuba II, Heymach JV, Lou G, Shao L, He Q, Lin C, Wu X, Shao YW, Wang X, He J, Chen Y, Stebbing J, Chen M, Zhang J, Yu X. Distinct co-acquired alterations and genomic evolution during TKI treatment in non-small-cell lung cancer patients with or without acquired T790M mutation. Oncogene 39(9):1846-1859, 2020. e-Pub 2020. PMID: 31754213.
53. Jin Y, Bao H, Le X, Fan X, Tang M, Shi X, Zhao J, Yan J, Xu Y, Quek K, Elamin YY, Zhang J, Futreal PA, Wistuba II, Heymach JV, Lou G, Shao L, He Q, Lin C, Wu X, Shao YW, Wang X, He J, Chen Y, Stebbing J, Chen M, Zhang J, Yu X. Correction: Distinct co-acquired alterations and genomic evolution during TKI treatment in non-small-cell lung cancer patients with or without acquired T790M mutation. Oncogene 39(9):2027, 2020. e-Pub 2020. PMID: 31831835.
54. Toomey S, Carr A, Mezynski MJ, Elamin Y, Rafee S, Cremona M, Morgan C, Madden S, Abdul-Jalil KI, Gately K, Farrelly A, Kay EW, Kennedy S, O'Byrne K, Grogan L, Breathnach O, Morris PG, Eustace AJ, Fay J, Cummins R, O'Grady A, Kalachand R, O'Donovan N, Kelleher F, O'Reilly A, Doherty M, Crown J, Hennessy BT. Identification and clinical impact of potentially actionable somatic oncogenic mutations in solid tumor samples. J Transl Med 18(1):99, 2020. e-Pub 2020. PMID: 32087721.
55. Robichaux JP, Elamin YY, Vijayan RSK, Nilsson MB, Hu L, He J, Zhang F, Pisegna M, Poteete A, Sun H, Li S, Chen T, Han H, Negrao MV, Ahnert JR, Diao L, Wang J, Le X, Meric-Bernstam F, Routbort M, Roeck B, Yang Z, Raymond VM, Lanman RB, Frampton GM, Miller VA, Schrock AB, Albacker LA, Wong KK, Cross JB, Heymach JV. Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity. Cancer Cell 36(4):444-457.e7, 2019. e-Pub 2019. PMID: 31588020.
56. Sagiv O, Ding S, Ferrarotto R, Glisson B, Altan M, Johnson F, Elamin Y, Thakar SD, Nagarajan P, Esmaeli B. Impact of Food and Drug Administration Approval of Vismodegib on Prevalence of Orbital Exenteration as a Necessary Surgical Treatment for Locally Advanced Periocular Basal Cell Carcinoma. Ophthalmic Plast Reconstr Surg 35(4):350-353, 2019. e-Pub 2019. PMID: 30365473.
57. Elamin YY Gomez DR, Antonoff MB, Robichaux JP, Tran H, Shorter MK, Bohac JM, Negrao MV, Le X, Rinsurogkawong W, Lewis J, Lacerda L, Roarty EB, Swisher SG, Roth JA, Zhang J, Papadimitrakopoulou V, Heymach JV. Local Consolidation Therapy (LCT) After First Line Tyrosine Kinase Inhibitor (TKI) for Patients With EGFR Mutant Metastatic Non-small-cell Lung Cancer (NSCLC). Clin Lung Cancer 20(1):43-47, 2019. e-Pub 2019. PMID: 30343004.
58. Le X, Puri S, Negrao MV, Nilsson MB, Robichaux J, Boyle T, Hicks JK, Lovinger KL, Roarty E, Rinsurongkawong W, Tang M, Sun H, Elamin Y, Lacerda LC, Lewis J, Roth JA, Swisher SG, Lee JJ, William WN, Glisson BS, Zhang J, Papadimitrakopoulou VA, Gray JE, Heymach JV. Landscape of EGFR -dependent and -independent resistance mechanisms to osimertinib and continuation therapy post-progression in EGFR-mutant NSCLC. Clin Cancer Res 24(24):6195-6203, 2018. e-Pub 2018. PMID: 30228210.
59. Skoulidis F, Goldberg ME, Greenawalt DM, Hellmann MD, Awad MM, Gainor JF, Schrock AB, Hartmaier RJ, Trabucco SE, Gay L, Ali SM, Elvin JA, Singal G, Ross JS, Fabrizio D, Szabo PM, Chang H, Sasson A, Srinivasan S, Kirov S, Szustakowski J, Vitazka P, Edwards R, Bufill JA, Sharma N, Ou SI, Peled N, Spigel DR, Rizvi H, Aguilar EJ, Carter BW, Erasmus J, Halpenny DF, Plodkowski AJ, Long NM, Nishino M, Denning WL, Galan-Cobo A, Hamdi H, Hirz T, Tong P, Wang J, Rodriguez-Canales J, Villalobos PA, Parra ER, Kalhor N, Sholl LM, Sauter JL, Jungbluth AA, Mino-Kenudson M, Azimi R, Elamin YY, Zhang J, Leonardi GC, Jiang F, Wong KK, Lee JJ, Papadimitrakopoulou VA, Wistuba II, Miller VA, Frampton GM, Wolchok JD, Shaw AT, Jänne PA, Stephens PJ, Rudin CM, Geese WJ, Albacker LA, Heymach JV. STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma. Cancer Discov 8(7):822-835, 2018. e-Pub 2018. PMID: 29773717.
60. Robichaux JP, Elamin YY, Tan Z, Carter BW, Zhang S, Liu S, Li S, Chen T, Poteete A, Estrada-Bernal A, Le AT, Truini A, Nilsson MB, Sun H, Roarty E, Goldberg SB, Brahmer JR, Altan M, Lu C, Papadimitrakopoulou V, Politi K, Doebele RC, Wong KK, Heymach JV. Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer. Nat Med 24(5):638-646, 2018. e-Pub 2018. PMID: 29686424.
61. Elamin YY, Rafee S, Toomey S, Hennessy BT. Immune effects of bevacizumab: killing two birds with one stone. Cancer Microenviron 8(1):15-21, 2015. e-Pub 2015. PMID: 25326055.
62. Rafee S, Elamin YY, Joyce E, Toner M, Flavin R, McDermott R, Sheehy N, Hennessy B, O'Byrne K, Gleeson N, Osman N. Neoadjuvant crizotinib in advanced inflammatory myofibroblastic tumour with ALK gene rearrangement. Tumori 101(2):e35-9, 2015. e-Pub 2015. PMID: 25744866.
63. Osman N, Elamin YY, Rafee S, O'Brien C, Stassen LF, Timon C, Kinsella J, Brennan S, O'Byrne KJ. Weekly cisplatin concurrently with radiotherapy in head and neck squamous cell cancer: a retrospective analysis of a tertiary institute experience. Eur Arch Otorhinolaryngol 271(8):2253-9, 2014. e-Pub 2014. PMID: 24121822.
64. Shikhrakab H, Elamin YY, O'Brien C, Gately K, Finn S, O'Byrne K, Osman N. Epidermal growth factor receptor (EGFR) mutation testing, from bench to practice: a single institute experience. Ir Med J 107(7):201-4, 2014. e-Pub 2014. PMID: 25226713.
65. Rafee S, Elamin YY, Cronin K, Brennan S, Osman N. A rare case of nasopharyngeal carcinoma with widespread CNS metastases. Ir Med J 107(6):180-1, 2014. e-Pub 2014. PMID: 24988837.

Invited Articles

1. Elamin Y, Papadimitrakopoulou VA. The Road MAP to Targeted Therapy in Squamous-Cell Carcinoma: Lung Cancer Master Protocol (SWOG S1400) Overview. Personalized Medicine in Oncology(6(1)), 2017. e-Pub 2017.

Review Articles

1. Holla VR, Elamin YY, Bailey AM, Johnson AM, Litzenburger BC, Khotskaya YB, Sanchez NS, Zeng J, Shufean MA, Shaw KR, Mendelsohn J, Mills GB, Meric-Bernstam F, Simon GR. ALK: a tyrosine kinase target for cancer therapy. Cold Spring Harb Mol Case Stud 3(1):a001115, 2017. e-Pub 2017. PMID: 28050598.
2. Elamin YY, Rafee S, Osman N, O Byrne KJ, Gately K. Thymidine Phosphorylase in Cancer; Enemy or Friend?. Cancer Microenviron 9(1):33-43, 2016. e-Pub 2016. PMID: 26298314.

Other Articles

1. Skoulidis, F, Araujo, HA, Do, MT, Qian, Y, Sun, X, Cobo, AG, Le, JT, Montesion, M, Palmer, R, Jahchan, NS, Juan, J, Min, C, Yu, Y, Pan, X, Arbour, KC, Vokes, N, Schmidt, S, Molkentine, D, Owen, D, Memmott, R, Patil, P, Marmarelis, ME, Awad, MM, Murray, J, Hellyer, JA, Gainor, J, Dimou, A, Bestvina, CM, Shu, CA, Riess, JW, Blakely, CM, Pecot, CV, Mezquita, L, Tabbò, F, Scheffler, M, Digumarthy, S, Mooradian, MJ, Sacher, A, Lau, SC, Saltos, A, Rotow, JK, Johnson, RP, Liu, C, Stewart, TF, Goldberg, SB, Killam, J, Walther, Z, Schalper, K, Davies, KD, Woodcock, MG, Anagnostou, V, Marrone, KA, Forde, PM, Ricciuti, B, Venkatraman, D, Van Allen, EM, Cummings, AL, Goldman, JW, Shaish, H, Kier, M, Katz, S, Aggarwal, C, Ni, Y, Azok, J, Segal, J, Ritterhouse, LL, Neal, JW, Lacroix, L, Elamin, YY, Vailati Negrao, M, Le, X, Lam, VK, Lewis, WE, Kemp, HN, Carter, B, Roth, JA, Swisher, S, Lee, R, Zhou, T, Poteete, A, Kong, Y, Takehara, T, Paula, AG, Parra Cuentas, ER, Behrens, MC, Wistuba, II, Zhang, J, Blumenschein, GR, Gay, CM, Byers, LA, Gibbons, DL, Tsao, A, Lee, JJ, Bivona, T, Camidge, DR, Gray, JE, Leighl, NB, Levy, BP, Brahmer, JR, Garassino, MC, Gandara, D, Garon, EB, Rizvi, NA, Scagliotti, G, Wolf, J, Planchard, D, Besse, B, Herbst, RS, Wakelee, HA, Pennell, N, Shaw, AT, Jänne, PA, Carbone, DP, Hellmann, MD, Rudin, CM, Albacker, LA, Mann, H, Zhu, Z, Lai, Z, Stewart, RA, Peters, S, Johnson, M, Wong, KK, Huang, A, Winslow, MM, Rosen, MJ, Winters, IP, Papadimitrakopoulou, VA, Cascone, T, Jewsbury, P, Heymach, JV Correction to. Nature 639(8054):E19, 2025. PMID: 40016449.
2. Skoulidis, F, Araujo, HA, Do, MT, Qian, Y, Sun, X, Cobo, AG, Le, JT, Montesion, M, Palmer, R, Jahchan, NS, Juan, J, Min, C, Yu, Y, Pan, X, Arbour, KC, Vokes, N, Schmidt, S, Molkentine, D, Owen, D, Memmott, R, Patil, P, Marmarelis, ME, Awad, MM, Murray, J, Hellyer, JA, Gainor, J, Dimou, A, Bestvina, CM, Shu, CA, Riess, JW, Blakely, CM, Pecot, CV, Mezquita, L, Tabbò, F, Scheffler, M, Digumarthy, S, Mooradian, MJ, Sacher, A, Lau, SC, Saltos, A, Rotow, JK, Johnson, RP, Liu, C, Stewart, TF, Goldberg, SB, Killam, J, Walther, Z, Schalper, K, Davies, KD, Woodcock, MG, Anagnostou, V, Marrone, KA, Forde, PM, Ricciuti, B, Venkatraman, D, Van Allen, EM, Cummings, AL, Goldman, JW, Shaish, H, Kier, M, Katz, S, Aggarwal, C, Ni, Y, Azok, J, Segal, J, Ritterhouse, LL, Neal, JW, Lacroix, L, Elamin, YY, Vailati Negrao, M, Le, X, Lam, VK, Lewis, WE, Kemp, HN, Carter, B, Roth, JA, Swisher, S, Lee, R, Zhou, T, Poteete, A, Kong, Y, Takehara, T, Paula, AG, Parra Cuentas, ER, Behrens, MC, Wistuba, II, Zhang, J, Blumenschein, GR, Gay, CM, Byers, LA, Gibbons, DL, Tsao, A, Lee, JJ, Bivona, T, Camidge, DR, Gray, JE, Leighl, NB, Levy, BP, Brahmer, JR, Garassino, MC, Gandara, D, Garon, EB, Rizvi, NA, Scagliotti, G, Wolf, J, Planchard, D, Besse, B, Herbst, RS, Wakelee, HA, Pennell, N, Shaw, AT, Jänne, PA, Carbone, DP, Hellmann, MD, Rudin, CM, Albacker, LA, Mann, H, Zhu, Z, Lai, Z, Stewart, RA, Peters, S, Johnson, M, Wong, KK, Huang, A, Winslow, MM, Rosen, MJ, Winters, IP, Papadimitrakopoulou, VA, Cascone, T, Jewsbury, P, Heymach, JV Correction to. Nature 639(8054):E19, 2025. PMID: 40016449.
3. Robichaux JP, Elamin YY, Tan Z, Carter BW, Zhang S, Liu S, Li S, Chen T, Poteete A, Estrada-Bernal A, Le AT, Truini A, Nilsson MB, Sun H, Roarty E, Goldberg SB, Brahmer JR, Altan M, Lu C, Papadimitrakopoulou V, Politi K, Doebele RC, Wong KK, Heymach JV Author Correction: Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer. Nat Med 30(9):2694-2695, 2024. PMID: 39164519.

Abstracts

1. Elamin YY, Gandhi S, Antonoff M, Gibbons D, Negrao MV, Cascone T, Gay CM, Byers LA, Blumenschein G, Rusthoven CG, Vaporciyan A, Blakely CM, Gomez D, Feng L, Zhang J, Altan M, Le X, Chang JY, Swisher S, Heymach J. NorthStar: A Phase II Randomized Study of Osimertinib (OSI) With or Without Local Consolidative Therapy (LCT) for Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC). Ann Oncol 36, 2025. e-Pub 2025.
2. Drilon A, Dziadziuszko R, Camidge DR, Lin JJ, Besse B, Kim SW, Lee KH, Solomon B, Nagasaka M, Goto K, Wolf J, de Langen AJ, Cheema P, Yang N, Velcheti V, Elamin Y, Xu Y, Calvet CY, Ades F, Cho BC. Repotrectinib in tyrosine kinase inhibitor (TKI)-naïve patients (pts) with advanced ROS1 fusion-positive (ROS1+) NSCLC in the phase 1/2 TRIDENT-1 trial: Clinical update, treatment beyond progression and subsequent therapies. J Clin Oncol 42, 2024.
3. Elamin YY, Nagasaka M, Shum E, Bazhenova L, Camidge D, Cho BC, Felip E, Goto K, Lin C, Piotrowska Z, Planchard D, Rotow JK, Spigel DR, Tan DS, Yoshida T, Minchom AR, Langen AD, Kato T, Zalutskaya A, Reckamp KL. BLU-945 monotherapy and combination with osimertinib in previously treated patients with advanced EGFR-mutant (EGFRm) NSCLC in phase 1/2 SYMPHONY study 41, 2023. e-Pub 2023.
4. Patil T, Carrizosa DR, Burkard ME, Reckamp KL, Desai J, Chae YK, Liu SV, Konduri K, Gadgeel SM, Lin JJ, Cheema PK, Spigel DR, Schram AM, Jansen VM, Elamin YY. CRESTONE: A Phase 2 study of seribantumab in adult patients with neuregulin-1 (NRG1) fusion positive locally advanced or metastatic solid tumors. Cancer Res 83, 2023. e-Pub 2023.
5. Elamin YY, Gandhi S, Antonoff, Mott F, Gibbons DL, Le X, Negrao MV, Sepesi B, Karam JA, Cascone T, Wang L, Blumenschein G, Glisson BS, Tsao AS, Heymach JV. BRIGHTSTAR: A pilot trial of local consolidative therapy (LCT) with brigatinib in tyrosine kinase inhibitor (TKI)-naïve ALK-rearranged advanced NSCLC, 2020. e-Pub 2020.
6. Elamin YY, Robichaux JP, Carter B, Altan M, Gibbons DL, Fossella F, Simon GR, Lam V, Blumenschein G, Tsao A, Kurie J, Mott FE, Negrao MV, Hu L, He J, Nilsson M, Roeck B, Yang Z, Papadimitrakopoulou VA, Heymach JV. Identification of Mechanisms of Acquired Resistance to Poziotinib in EGFR Exon 20 Mutant Non-Small Cell Lung Cancer (NSCLC, 2019. e-Pub 2019.
7. Elamin YY, Robichaux JP, Lam V, Tsao A, Lu C, Blumenschein G, Kurie J, Brahmer J, Liu S, Li S, Chen T, Estrada-Bernal A, Truini A, Nilsson MB, Tan Z, Zhang S, Politi K, Doebele RC, Yang Z, Wong KK, Heymach JV. The preclinical and clinical activity of poziotinib, a potent, selective inhibitor of EGFR exon 20 mutant NSCLC, 2017. e-Pub 2017.
8. Skoulidis F, Elamin YY, Papadimitrakopoulou V, Tong P, Lewis J, Rinsurongkawong, Chu C, Roarty B, Zhang J, Tran H, Rodriguez-Canales J, Parra ER, Behrens C, Kadara H, Wistuba II, Heymach JV. Impact of major co-mutations on the immune contexture and response of KRAS-mutant lung adenocarcinoma to immunotherapy, 2017. e-Pub 2017.
9. Tran HT, Elamin YY, Simon GR, Blumenschein GR, Tsao AS, Papadimitrakopoulou V, Gibbons DL, Fossella FV, Lanman RB, Banks KC, Byers LA, Zhang J, Heymach JV. Clinical utilization of a CLIA-certified cell-free DNA (cfDNA) blood test for identification of targetable molecular alterations in patients with non-small cell lung cancer (NSCLC), 2016. e-Pub 2016.
10. Elamin YY, Xia D, Gold KA, Byers LA, Fan YH, Diao L, Wang J, Giri U, Gudikote J, Tran HT, Heymach JV. Reprogramming of cell signaling in response to MEK inhibition in non-small cell cancer (NSCLC), 2016. e-Pub 2016.
11. Elamin YY, Rinsurongkawong W, Tran HT, Gold KA, Lewis J, Roarty EB, FutrealA, Zhang J, Heymach JV. The impact of genomic landscape of EGFR mutant NSCLC on response to targeted and immune therapy, 2016. e-Pub 2016.
12. Elamin YY, Toomey S, Carr A, Gately K, Rafee S, Grogan W, Morris PG, Breathnach OS, Crown J, O’Byrne K, Hennessy BT. Protein tyrosine phosphatase non receptor 11 (PTPN11/Shp2) as a driver oncogene and a novel therapeutic target in non-small cell lung cancer (NSCLC), 2015. e-Pub 2015.
13. Rafee S, Toomey S, Elamin YY, Carr A, Gately K, Finn S, Nicholson S, Cuffe S, Crown J, Morris PG, Grogan W, Breathnach OS, Kay E, O’Grady A, Hennessy BT, O’Byrne K. Identifying driver mutations in squamous cell lung cancer (SCC): The Lung Cancer Genomics Ireland (LCGI) study, 2015. e-Pub 2015.
14. Rafee S, Elamin YY, Toomey S, Gately K, Carr A, Cuffe S, Nicholson S, Fin SP, Ryan R, Young V, Crown J, Breathnach O, Morris P, Kay E, O’Grady A, Hennessy B, O’Byrne K. Co-occurrence of driver mutations of MAPK and PI3K pathways in non-small cell lung cancer: a report from the Lung Cancer genomics Ireland (LCGI) study, 2015. e-Pub 2015.
15. Rafee S, Toomey S, Elamin YY, Gately K, Carr A, Cuffe S, Nicholson S, Fin SP, Ryan R, Young V, Crown J, Breathnach O, Morris P, Kay E, O’Grady A, Hennessy B, O’Byrne K. Targetable genomic aberrations I squamous cell lung cancer : a report from the Lung Cancer genomics Ireland (LCGI) study, 2015. e-Pub 2015.
16. Elamin YY, Ebrahem H, Flynn A, O’Regan E, Brennan S, Osman N. Weekly Cisplatin Concurrently with Radiotherapy in Head Neck SCC, a retrospective analysis of a tertiary institute, 2014. e-Pub 2014.
17. Elamin YY, Toomey S, Carr A, Rafee S, Gately K, Cuffe S, O’Byrne K, Hennessy BT. The role of protein tyrosine phosphatase non-receptor 11 (PTPN11) mutations in Lung Squamous Cell Carcinoma (SQCC, 2014. e-Pub 2014.
18. Elamin YY, Geoghegan S, Mockler M, Parkinson B, Lysaght J. Ipilimumab; a new era in cancer therapy, case report, 2013. e-Pub 2013.
19. Elamin YY, Gleeson N, Darcy TJM, Kennedy MJ, O’Donnell DM. Surgery for Malignant Intestinal Obstruction Due to Ovarian Cancer, Survival, 2012. e-Pub 2012.
20. Elamin YY, Hayat A, Lavin M. Double hit lymphoma; the tip of the iceberg, 2011. e-Pub 2011.